
CLAIMS

1. Use of a compound having the general formula (XXI)



(XXI)

and pharmaceutically acceptable salts, hydrates and rotamers thereof;

in which

C^1 is selected from the group consisting of aryl and heteroaryl, in which the heteroaryl group has from 1-3 heteroatoms as ring members selected from N, O and S; and in which the aryl and heteroaryl groups are optionally substituted with from 1 to 3 R^1 substituents;

C^2 is selected from the group consisting of aryl and heteroaryl, in which the heteroaryl group has from 1-3 heteroatoms as ring members selected from N, O and S; and in which the aryl and heteroaryl groups are optionally substituted with from 1 to 3 R^2 substituents;

C^3 is selected from the group consisting of C_{1-8} alkyl or heteroalkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl-C_{1-4} alkyl, aryl, aryl-C_{1-4} alkyl, heteroaryl, heteroaryl-C_{1-4} alkyl, heterocycloalkyl or heterocycloalkyl-C_{1-4} alkyl, in which the heteroalkyl group has from 1-3 heteroatoms selected from N, O and S, in which the heterocycloalkyl group or portion has from 1-3 heteroatoms selected from N, O and S, and in which the heteroaryl group has from 1-3 heteroatoms as ring members selected from N, O and S, and each C^3 is optionally substituted with from 1 to 3 R^3 substituents;

each R^1 is independently selected from the group consisting of halogen, —CN, -R^c, —CO_2R^a, —$CONR^aR^b$, —$C(O)R^a$, —$OC(O)NR^aR^b$, —$NR^bC(O)R^a$, —$NR^bC(O)_2R^c$, —NR^a—$C(O)NR^aR^b$, —$NR^aC(O)NR^aR^b$, —NR^aR^b, —OR^a, and —$S(O)_2NR^aR^b$; in which each R^a and R^b is independently selected from hydrogen, C_{1-8} alkyl, and C_{1-8} haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring

members selected from N, O or S, and is optionally substituted with one or two oxo; each R^c is independently selected from the group consisting of C_{1-8} alkyl or heteroalkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, heterocycloalkyl, aryl and heteroaryl, and in which the aliphatic and/or cyclic portions of R^a, R^b and R^c are optionally further substituted with from one to three halogen, hydroxy, methyl, amino, alkylamino and dialkylamino groups; and optionally when two R^1 substituents are on adjacent atoms, are combined to form a fused five or six-membered carbocyclic or heterocyclic ring;

each R^2 is independently selected from the group consisting of halogen, —CN, —NO_2, —R^f, —CO_2R^d, —$CONR^dR^e$, —$C(O)R^d$, —$OC(O)NR^dR^e$, —$NR^eC(O)R^d$, —$NR^eC(O)_2R^f$, —$NR^dC(O)NR^dR^e$, —NR^dR^e, —OR^d, and —$S(O)_2NR^dR^e$; in which each R^d and R^e is independently selected from hydrogen, C_{1-8} alkyl, and C_{1-8} haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O or S, and is optionally substituted with one or two oxo; each R^f is independently selected from the group consisting of C_{1-8} alkyl or heteroalkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, heterocycloalkyl, aryl and heteroaryl, and in which the aliphatic and/or cyclic portions of R^d, R^e and R^f are optionally further substituted with from one to three halogen, hydroxy, methyl, amino, alkylamino and dialkylamino groups, and optionally when two R^2 groups are on adjacent atoms, they are combined to form a five- or six-membered ring;

each R^3 is independently selected from the group consisting of halogen, —CN, —R^i, —CO_2R^g, —$CONR^gR^h$, —$C(O)R^g$, —$C(O)R^i$, —$OC(O)NR^gR^h$, —$NR^hC(O)R^g$, —$NR^hCO_2R^i$, —$NR^gC(O)NR^gR^h$, —NR^gR^h, —OR^g, —OR^j, —$S(O)_2NR^gR^h$, —X^4—R^j, —NH—X^4—R^j, —O—X^4—R^j, —X^4—NR^gR^h, —X^4—NHR^j, —X^4—$CONR^gR^h$, —X^4—$NR^hC(O)R^g$, —X^4—CO_2R^g, —O—X^4—CO_2R^g, —NH—X^4—CO_2R^g, —X^4—$NR^hCO_2R^i$, —O—X^4—$NR^hCO_2R^i$, —NHR^j and —$NHCH_2R^j$, in which X^4 is a C_{1-4} alkylene; each R^g and R^h is independently selected from hydrogen, C_{1-8} alkyl or heteroalkyl, C_{3-6} cycloalkyl and C_{1-8} haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a four-, five- or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O or S and is optionally substituted with one or two oxo; each R^i is independently selected from the group consisting of C_{1-8} alkyl or heteroalkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, heterocycloalkyl, aryl and heteroaryl; and each R^j is selected from the group consisting

of C_{3-6} cycloalkyl, imidazolyl, pyrimidinyl, pyrrolinyl, pyrrolyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and S,S-dioxo-tetrahydrothiopyranyl, and in which the aliphatic and/or cyclic portions of R^g, R^h, R^i and R^j are optionally further substituted with from one to three halogen, methyl, CF_3, hydroxy, C_{1-4} alkoxy, C_{1-4} alkoxy-C_{1-4} alkyl, —C(O)O—C_{1-8} alkyl, amino, alkylamino and dialkylamino groups, and optionally when two R^3 groups are on adjacent atoms, they are combined to form a five- or six-membered ring;

X is hydrogen or CH_3; and

R^8 and R^9 are independently from each other selected from the group consisting of hydrogen, halogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, and C_1-C_8 alkoxy or R^8 and R^9 are combined to form a fused saturated or unsaturated mono- or multi-ring carbocycle in which one or more of the ring carbon atoms may be replaced independently from each other by N, S, or O,

in the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of

monosodium urate (MSU)-inducible diseases,


neutrophil-driven inflammatory kidney diseases,

cutaneous neutrophilic inflammatory diseases, and

immune complex diseases.


2. Use according to Claim 1, in which at least one of R^8 and R^9 is **not** hydrogen and/or in which X is hydrogen.

3. Use according to Claim 1 or 2, in which the compound has formula (XXIa)




(XXIa)

4. Use according to Claim 1, 2 or 3, in which the compound has formula (I) or formula (XI):




(I) or




(XI),

preferably has formula (Ia) or formula (XIa):



(Ia) or



(XIa),

in which

R^4 is selected from the group consisting of cyano, halo, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_1-C_6)alkyl-OH, (C_1-C_6)-alkyl-NR^5R^6, trifluoromethyl, (C_1-C_6)alkoxy, (C_1-C_6)thioalkoxy, phenoxy, COR^7, NR^5R^6, $NHCO(C_1$-$C_6)$ alkyl, SO_3H, $SO_2(C_1$-$C_6)$ alkyl and $SO_2NR^5R^6$;


R^5 and R^6 are each independently selected from the group consisting of hydrogen, (C_1-C_6)alkyl and (C_3-C_6)cycloalkyl;


R^7 is independently hydroxyl, (C_1-C_6)alkoxy, phenoxy or -NR^5R^6;


m is 0-4; and


CYCLE is a saturated or unsaturated mono- or multi-ring carbocycle in which one or more of the ring carbon atoms may be replaced independently from each other by N, S, or O.


5. Use according to any preceding claim, in which the compound has a formula selected from the group consisting of (II), (IIIa), (IIIb), (IIIc), and (IIId):


(II),



(IIIa),



(IIIb),



(IIIc), and



(IIId),

preferably has a formula selected from the group consisting of (IIa), (IIIe), (IIIf), (IIIg), and (IIIh):



(IIa),


(IIIe),


(IIIf),




(IIIg), and



(IIIh).

6. Use according to any preceding claim, in which C^1 is




,

in which

n is an integer selected from 0, 1, 2, or 3.

7. Use according to any preceding claim, in which C^2 is




,

in which

o is an integer selected from 0, 1, 2, or 3.

8. Use according to any one of claims 1 to 7, in which C^3 is




,

in which

p is an integer selected from 0, 1, 2, or 3.


9. Use according to any of Claims 1 to 4, 6, 7 or 8, in which R_8 is selected from the group consisting of halogen, C_1-C_4 alkyl, C_1-C_4 haloalkyl, and C_1-C_4 alkoxy; preferably from the group consisting of fluoro, chloro, methyl, trifluoromethyl, and methoxy.

10. Use according to any of Claims 1 to 8, in which the compound is selected from the group consisting of




INF004

,




INF011

,




INF014

,




INF015


,




INF022,




INF023,




INF024,




INF025,







INF030,




INF033,




INF034,




INF035,




INF038,




INF039,




INF040,




INF041,



INF045,




INF046,




INF047,


INF048,




INF049,




INF050,



INF051,




INF055, and




INF058.


11. Use according to any of Claims 1 to 4, 6, 7, 8, or 9, in which the compound is selected from the group consisting of




INF052,




INF053,




INF056,




INF067,




INF068,




INF069,




INF070,




INF071,




INF072,



INF075,





INF077, and **INF080.**

12. Use of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any any preceding claim in the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of

monosodium urate (MSU)-inducible diseases,

neutrophil-driven inflammatory kidney diseases,

cutaneous neutrophilic inflammatory diseases, and

immune complex diseases.

13. Use according to any preceding claim, in which the disease or disorder is selected from the group consisting of monosodium urate (MSU)-inducible diseases, including peritonitis and gout.

14. Use according to any of Claims 1 to 12, in which the disease or disorder is selected from the group consisting of neutrophil-driven inflammatory kidney diseases, including ischemic nephropathy, ischemic reperfusion renal injury, and obstructive nephropathy, or in which the disease or disorder is selected from the group consisting of cutaneous neutrophilic inflammatory diseases, including hidradenitis suppurativa (HS), pyoderma gangrenosum (PG), PASH (PG, acne, and hidradenitis suppurativa), PAPASH (pyogenic arthritis, acne, PG, and hidradenitis suppurativa), chronic spontaneous urticaria, and bullous pemphigoid.

15. Use according to any of Claims 1 to 12, in which the disease or disorder is selected from the group consisting of immune complex diseases, including rheumatoid arthritis, systemic lupus erythematosus (SLE), immune-complex mediated glomerulonephritis, IgA nephritis, lupus nephritis, ANCA (Antineutrophilic cytoplasmic antibody) vasculitis, anti-C3 glomerulopathy, atypical haemolytic uraemia syndrome (aHUS), Goodpasture syndrome,

crescentic glomerulonephritis, focal segmental glomerulosclerosis (FSGS), rheumatic fever, dermatomyositis, chronic inflammatory demyelinating polyneuropathy, chemotherapy-induced peripheral neuropathy, and transplantation rejection.